149 related articles for article (PubMed ID: 30391539)
1. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
[TBL] [Abstract][Full Text] [Related]
2. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
[TBL] [Abstract][Full Text] [Related]
3. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
[TBL] [Abstract][Full Text] [Related]
4. Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.
Dunkelmann T; Teichmann K; Ziehm T; Schemmert S; Frenzel D; Tusche M; Dammers C; Jürgens D; Langen KJ; Demuth HU; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neuropeptides; 2018 Feb; 67():27-35. PubMed ID: 29273382
[TBL] [Abstract][Full Text] [Related]
5. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers.
Elfgen A; Hupert M; Bochinsky K; Tusche M; González de San Román Martin E; Gering I; Sacchi S; Pollegioni L; Huesgen PF; Hartmann R; Santiago-Schübel B; Kutzsche J; Willbold D
Sci Rep; 2019 Apr; 9(1):5715. PubMed ID: 30952881
[TBL] [Abstract][Full Text] [Related]
6. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.
Dunkelmann T; Schemmert S; Honold D; Teichmann K; Butzküven E; Demuth HU; Shah NJ; Langen KJ; Kutzsche J; Willbold D; Willuweit A
J Alzheimers Dis; 2018; 63(1):115-130. PubMed ID: 29578479
[TBL] [Abstract][Full Text] [Related]
8. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
[TBL] [Abstract][Full Text] [Related]
9. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
[TBL] [Abstract][Full Text] [Related]
10. Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
Klein AN; Ziehm T; van Groen T; Kadish I; Elfgen A; Tusche M; Thomaier M; Reiss K; Brener O; Gremer L; Kutzsche J; Willbold D
ACS Chem Neurosci; 2017 Sep; 8(9):1889-1900. PubMed ID: 28581708
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the
Willuweit A; Humpert S; Schöneck M; Endepols H; Burda N; Gremer L; Gering I; Kutzsche J; Shah NJ; Langen KJ; Neumaier B; Willbold D; Drzezga A
Eur J Pharm Sci; 2023 May; 184():106421. PubMed ID: 36889654
[TBL] [Abstract][Full Text] [Related]
13. Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation.
Zhang T; Gering I; Kutzsche J; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2019 Dec; 10(12):4800-4809. PubMed ID: 31710458
[TBL] [Abstract][Full Text] [Related]
14. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo.
Kass B; Schemmert S; Zafiu C; Pils M; Bannach O; Kutzsche J; Bujnicki T; Willbold D
Cell Rep Med; 2022 May; 3(5):100630. PubMed ID: 35584626
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
[TBL] [Abstract][Full Text] [Related]
16. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
Wirths O; Breyhan H; Cynis H; Schilling S; Demuth HU; Bayer TA
Acta Neuropathol; 2009 Oct; 118(4):487-96. PubMed ID: 19547991
[TBL] [Abstract][Full Text] [Related]
17. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?
Willbold D; Kutzsche J
Molecules; 2019 Jun; 24(12):. PubMed ID: 31208037
[TBL] [Abstract][Full Text] [Related]
18. High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.
Robb E; Perez K; Hung LW; Masters CL; Barnham KJ; Cherny RA; Bush AI; Adlard PA; Finkelstein DI
J Alzheimers Dis; 2015; 44(1):69-78. PubMed ID: 25182735
[TBL] [Abstract][Full Text] [Related]
19. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
[TBL] [Abstract][Full Text] [Related]
20. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.
Ferrera D; Mazzaro N; Canale C; Gasparini L
Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
